Mitchell Martan
Investment Researcher for The Long Investor, Economics/Finance Background
Coupang is too cheap here and offers great risk/reward, with heavy insider buying signaling confidence. Director Neil Mehta bought $138M of stock this week, which @Mr_Derivatives tallies at $158M over three days. It also remained one of Stanley Druckenmiller's biggest holdings last quarter, when he likely added more. x.com x.comÂ
Coupang insiders bought a massive $158 million of stock over the last three days, a whale worth tailing. x.comÂ
Coupang looks like a long-term buy on a typical reversal pattern coupled with a large insider purchase. Per @BourbonInsider, a director just bought 7M shares for about $136.6M at prices of $18.48 to $19. x.comÂ
Coupang is a phenomenal buy because a board member just bought $136 million of stock, probably the largest non-founder insider purchase ever seen, and there is only one reason to do that. It trades at about 20x next-12-month EBITDA, with EBITDA expected to grow about 30% a year for the next few years, though margins compress slightly this year on Taiwan expansion. Versus Sea, Coupang looks a little cheaper after being overly punished for its data breach. x.com x.com x.comÂ
Coupang counts Kevin Warsh, a board member since 2019, among its shareholders, a signal that justifies buying more. x.com x.comÂ
Teva is a Stage 2 uptrend backed by strong earnings, with back-to-back power earnings gaps showing heavy accumulation. It is also Stanley Druckenmiller's fifth-largest holding. Teva is a leading maker of generics, innovative medicines and biosimilars. x.comÂ
